Osteoarthritis disease progression model using six year follow-up data from the osteoarthritis initiative

Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2015, Pages 269-278

  Passey, Chaitali ^a   Kimko, Holly ^b   Nandy, Partha ^b   Kagan, Leonid ^a  

^a RUTGERS UNIVERSITY   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

disease progression; Knee osteoarthritis; non linear mixed effects modeling; WOMAC

Indexed keywords

ADULT; AGED; ANALGESIA; ARTICLE; CAUCASIAN; COHORT ANALYSIS; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; RACE DIFFERENCE; SEX DIFFERENCE; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; CLINICAL TRIAL; FACTUAL DATABASE; HEALTH STATUS; INCIDENCE; KNEE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONLINEAR SYSTEM; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR;

AGED; DATABASES, FACTUAL; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; INCIDENCE; KNEE JOINT; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONLINEAR DYNAMICS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS;

EID: 84960350036     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.399     Document Type: Article

References (40)

1. Abramson SB, Attur M, Yazici Y,. Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol. 2006; 2 (6): 304-312.
2. Karsdal MA, Bay-Jensen AC, Henriksen K, Christiansen C,. The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation: may estrogen be a magic bullet?. Menopause Int. 2012; 18 (4): 139-146.
3. Peat G, McCarney R, Croft P,. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis. 2001; 60 (2): 91-97.
4. Dunlop DD, Manheim LM, Yelin EH, Song J, Chang RW,. The costs of arthritis. Arthritis Rheum. 2003; 49 (1): 101-113.
5. Kalunian KC,. Pathogenesis of osteoarthritis. Available at: http://www.uptodate.com Accessed 10/11/2012, 2013.
6. Altman RD,. Criteria for the classification of osteoarthritis of the knee and hip. Scand J Rheumatol Suppl. 1987; 65: 31-39.
7. Kornaat PR, Bloem JL, Ceulemans RY, et al., Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology. 2006; 239 (3): 811-817.
8. Barker K, Lamb SE, Toye F, Jackson S, Barrington S,. Association between radiographic joint space narrowing, function, pain and muscle power in severe osteoarthritis of the knee. Clin Rehabil. 2004; 18 (7): 793-800.
9. Link TM, Steinbach LS, Ghosh S, et al., Osteoarthritis: MR imaging findings in different stages of disease and correlation with clinical findings. Radiology. 2003; 226 (2): 373-381.
10. Bliddal H, Christensen R,. The treatment and prevention of knee osteoarthritis: a tool for clinical decision-making. Expert Opin Pharmacother. 2009; 10 (11): 1793-1804.
11. Lalonde RL, Kowalski KG, Hutmacher MM, et al., Model-based drug development. Clin Pharmacol Ther. 2007; 82 (1): 21-32.
12. Gobburu JV, Lesko LJ,. Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol. 2009; 49: 291-301.
13. Administration FaD. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. 2004.
14. Holford NH, Peace KE,. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992; 89 (23): 11471-11475.
15. de Winter W, DeJongh J, Post T, et al., A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn. 2006; 33 (3): 313-343.
16. Ploeger BA, Holford NH,. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat. 2009; 8 (3): 225-238.
17. Samtani MN, Raghavan N, Shi Y, et al., Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol. 2013; 75 (1): 146-161.
18. Schmidt S, Post TM, Boroujerdi MA, et al., Disease progression analysis: towards mechanism-based models. In:, Kimko H, Peck CC, eds. Clinical Trial Simulations: Applications and Trends. Springer; 2011: 437-459.
19. Illingworth KD, El Bitar Y, Siewert K, Scaife SL, El-Amin S, Saleh KJ,. Correlation of WOMAC and KOOS scores to tibiofemoral cartilage loss on plain radiography and 3 Tesla MRI: data from the osteoarthritis initiative. Knee Surg Sports Traumatol Arthrosc. 2014; 22 (7): 1649-1658.
20. Collins NJ, Misra D, Felson DT, Crossley KM, Roos EM,. Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS). Arthritis Care Res. 2011; 63 (S11): S208-S228.
21. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC),. Available at: http://www.rheumatology.org/practice/clinical/clinicianresearchers/outcomes-instrumentation/WOMAC.asp Accessed 2013.
22. Bellamy N,. WOMAC Osteoarthritis Index user guide. Version V. Brisbane. Australia; 2002.
23. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW,. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988; 15 (12): 1833-1840.
24. Wright JG, Young NL,. A comparison of different indices of responsiveness. J Clin Epidemiol. 1997; 50 (3): 239-246.
25. Lindbom L, Ribbing J, Jonsson EN,. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004; 75 (2): 85-94.
26. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58 (1): 51-64.
27. Cooper C, Adachi JD, Bardin T, et al., How to define responders in osteoarthritis. Curr Med Res Opin. 2013; 29 (6): 719-729.
28. Pelletier JP, Martel-Pelletier J,. Imaging in osteoarthritis trials: useful or just expensive?. Nat Clin Pract Rheumatol. 2009; 5 (2): 76-77.
29. Roubille C, Pelletier JP, Martel-Pelletier J,. New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?. Expert Opin Pharmacother. 2013; 14 (15): 2059-2077.
30. Mould DR,. Models for disease progression: new approaches and uses. Clin Pharmacol Ther. 2012; 92 (1): 125-131.
31. Allen KD,. The value of measuring variability in osteoarthritis pain. J Rheumatol. 2007; 34 (11): 2132-2133.
32. Leyland KM, Hart DJ, Javaid MK, et al., The natural history of radiographic knee osteoarthritis: a fourteen-year population-based cohort study. Arthritis Rheum. 2012; 64 (7): 2243-2251.
33. Soni A, Kiran A, Hart DJ, et al., Prevalence of reported knee pain over twelve years in a community-based cohort. Arthritis Rheum. 2012; 64 (4): 1145-1152.
34. Kumm J, Tamm A, Lintrop M, Tamm A,. The prevalence and progression of radiographic knee osteoarthritis over 6 years in a population-based cohort of middle-aged subjects. Rheumatol Int. 2012; 32 (11): 3545-3550.
35. Sharif M, Kirwan JR, Elson CJ, Granell R, Clarke S,. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum. 2004; 50 (8): 2479-2488.
36. Reginster JY, Badurski J, Bellamy N, et al., Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis. 2013; 72 (2): 179-186.
37. McAlindon T, LaValley M, Schneider E, et al., Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA. 2013; 309 (2): 155-162.
38. Bingham CO, 3rd, Buckland-Wright JC, Garnero P,. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006; 54 (11): 3494-3507.
39. Bjordal JM, Klovning A, Ljunggren AE, Slordal L,. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007; 11 (2): 125-138.
40. Riddle DL, Stratford PW,. Unilateral vs bilateral symptomatic knee osteoarthritis: associations between pain intensity and function. Rheumatology (Oxford). 2013; 52 (12): 2229-2237.